TSE:ATE Antibe Therapeutics (ATE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsInsider Trades About Antibe Therapeutics Stock (TSE:ATE) 30 days 90 days 365 days Advanced Chart Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Antibe Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day RangeC$0.30▼C$0.3052-Week Range N/AVolume167,044 shsAverage Volume135,475 shsMarket CapitalizationC$15.64 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company OverviewAntibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.Read More… Receive ATE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ATE Stock News HeadlinesHow a mom of two who ‘ate her emotions’ lost over 120 pounds in under a yearAugust 3, 2024 | nypost.comCanadian Investment Regulatory Organization Trading Halt - ATEApril 9, 2024 | finance.yahoo.comWall St. Icon: “If you wait on this, it will already be too late”If you have a significant amount of money in the stock market right now — or if you're sitting on the sidelines waiting to make a move — you DO NOT want to miss my latest research.December 24, 2024 | InvestorPlace (Ad)Antibe Announces Unfavorable Decision in Arbitration With Nuance PharmaMarch 4, 2024 | finance.yahoo.comAntibe Extends Early Warrant Exercise Incentive ProgramFebruary 1, 2024 | finance.yahoo.comAntibe Therapeutics Inc ATEDecember 31, 2023 | morningstar.comAntibe Announces Early Warrant Exercise Incentive ProgramDecember 29, 2023 | finance.yahoo.comAntibe Reports Q2 2024 Interim Financial and Operating ResultsNovember 13, 2023 | finance.yahoo.comSee More Headlines ATE Stock Analysis - Frequently Asked Questions How do I buy shares of Antibe Therapeutics? Shares of ATE stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What other stocks do shareholders of Antibe Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Antibe Therapeutics investors own include Resverlogix (RVX), Royal Bank of Canada (RY), Tesla (TSLA), Unrivaled Brands (TRTC), Baytex Energy (BTE), Enbridge (ENB) and NVIDIA (NVDA). Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:ATE CUSIPN/A CIKN/A Webwww.antibethera.com Phone+1-905-5705103FaxN/AEmployees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-18,240,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-52.72% Return on Assets-19.13% Debt Debt-to-Equity Ratio0.29 Current Ratio10.06 Quick Ratio9.58 Sales & Book Value Annual SalesC$9.71 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow0.61 Book ValueC$0.49 per share Price / BookN/AMiscellaneous Outstanding Shares53,010,000Free FloatN/AMarket CapC$15.64 million OptionableNot Optionable Beta0.19 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (TSE:ATE) was last updated on 12/24/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredSix Stocks That Could Soar on Trump’s First Day BackThe recent election results have clarified a path forward, creating opportunities that weren't as clear just m...InvestorPlace | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Antibe Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Antibe Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.